Ipamorelin: A Complete Research Guide

Ipamorelin is a pentapeptide growth hormone secretagogue first described by Raun and colleagues at Novo Nordisk in the late 1990s. Among the GHRP (growth hormone releasing peptide) family, it is distinguished less by potency than by what it does not do: in published rodent and early human work, it elicits a growth hormone pulse without the concurrent rises in cortisol, prolactin, aldosterone, or acute appetite that characterize earlier GHRPs such as GHRP-6 and, to a lesser extent, GHRP-2. For researchers designing protocols where endocrine "cleanliness" matters, this selectivity is the reason the compound remains in the literature nearly three decades after its discovery.

Background and structural classification

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The aminoisobutyric acid (Aib) residue at the N-terminus confers resistance to peptidase cleavage, and the C-terminal amide is characteristic of the GHRP class. Molecular weight is approximately 711 Da. It was developed during a Novo Nordisk program searching for a GHRP-6 analogue retaining growth hormone releasing activity while minimizing off-target receptor binding.

Mechanistically, ipamorelin is an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor bound by endogenous ghrelin. Activation of GHS-R1a on somatotroph cells of the anterior pituitary triggers a phospholipase C–mediated cascade, elevating intracellular calcium and releasing stored growth hormone in a pulsatile fashion. Unlike growth hormone releasing hormone (GHRH) and its analogues, which act through a separate Gs-coupled receptor and primarily upregulate GH synthesis, GHRPs act on preformed GH stores and amplify pulse amplitude.

Ipamorelin is not a structural analogue of ghrelin itself — the ghrelin peptide is a 28-amino-acid chain with a characteristic octanoyl modification on Ser3. Rather, ipamorelin and the other small-molecule and peptide GHRPs were developed as minimalist ligands that retain GHS-R1a binding without the rest of the ghrelin molecule. This matters because ghrelin has documented effects on hypothalamic NPY/AgRP neurons driving food intake, and on cortisol and prolactin release through additional pathways. A ligand that binds GHS-R1a selectively, without engaging these downstream circuits as strongly, is the pharmacological target ipamorelin appears to hit.

The clean side-effect profile

The original Raun et al. 1998 paper in the European Journal of Endocrinology was specific on this point. In swine and rats, ipamorelin released growth hormone with potency and efficacy comparable to GHRP-6, but did not produce the dose-dependent elevations in ACTH, cortisol, or prolactin observed with the older peptide. Subsequent human pharmacology work, including a 2005 Gobburu et al. analysis of phase I data, confirmed that ipamorelin administration in healthy volunteers at doses up to several hundred micrograms did not meaningfully disturb cortisol or prolactin beyond baseline variation.

This selectivity profile is the feature most often cited in the literature. GHRP-6 is well known to drive acute hunger through central GHS-R1a activation in hypothalamic appetite circuits; GHRP-2 produces a milder but still measurable prolactin and cortisol bump. Ipamorelin, in the doses studied, does neither. The mechanism for this discrimination is not fully resolved — GHS-R1a is a single receptor — and likely involves differences in biased agonism, receptor conformation, and blood-brain barrier penetration across the GHRP class.

For research contexts, the practical implication is that ipamorelin can be administered without confounding cortisol or prolactin readouts, and without the pronounced post-injection appetite surge that complicates feeding-behavior or metabolic studies using GHRP-6. A 2017 review by Sinha and colleagues in the journal Endocrine grouped ipamorelin with MK-677 as "second-generation" secretagogues with improved endocrine specificity, though the two differ substantially in half-life and route.

Pulsatile GH release and why it matters

Endogenous growth hormone is secreted in discrete pulses — typically four to six significant peaks over a 24-hour period in adult humans, with the largest pulse occurring in the first few hours of slow-wave sleep. Between pulses, serum GH is nearly undetectable. This pulsatility is not incidental; downstream targets including hepatic IGF-1 production and peripheral tissue signaling appear to respond differently to pulsed versus continuous GH exposure, and sustained high GH levels (as in acromegaly or exogenous recombinant GH administration) produce a distinct pharmacological profile from pulsatile elevation.

GHRPs, including ipamorelin, work with this native architecture rather than overriding it. A subcutaneous ipamorelin dose produces a GH pulse lasting roughly 60 to 120 minutes, after which serum GH returns to baseline and somatotroph stores refill. Plasma half-life of ipamorelin itself is reported at approximately 2 hours in humans, consistent with this pulse duration. Receptor desensitization and somatostatin tone then gate further release for several hours.

This pharmacokinetic profile is what drives the dosing conventions seen across the research literature. Single large doses do not produce proportionally larger GH responses beyond a ceiling — somatotroph GH stores are finite, and somatostatin feedback rises. Multiple smaller doses spaced through the day produce a pulse pattern that more closely approximates physiological secretion. A 2012 study by Lall and colleagues in rodents reported that split dosing produced higher 24-hour integrated IGF-1 than equivalent total doses given as a single bolus, though human data on this specific comparison are limited.

Dosing ranges in the research literature

Published protocols and secondary analyses have described ipamorelin dosing in a relatively narrow band. Typical reported research doses fall between 100 and 300 micrograms per administration, delivered subcutaneously, with two to three administrations per day. The lower end (100 mcg) is commonly used in longer protocols where receptor sensitivity preservation is the priority; the upper end (300 mcg) approaches the ceiling above which additional dose does not reliably produce additional GH release.

Timing conventions reflect the pulsatile-release rationale. The three most common windows reported are:

• Morning, fasted. A pulse delivered before food intake avoids the blunting effect of elevated plasma glucose and free fatty acids on GH release. Insulin and glucose both suppress GH secretion acutely.
• Mid-afternoon or post-training. A second pulse timed to a period of naturally low endogenous GH, or following exercise when GH is already elevated.
• Pre-bed. A final pulse administered 30 to 60 minutes before sleep, intended to align with or augment the large endogenous slow-wave-sleep GH pulse.

The pre-bed timing is the most frequently discussed in the literature and in practitioner references. The logic is that the peptide-induced pulse and the endogenous sleep-onset pulse can overlap, producing a larger integrated GH exposure during the period when GH is believed to contribute most to overnight tissue repair and IGF-1 generation. Direct head-to-head human data comparing pre-bed versus other timings for ipamorelin specifically are sparse; the convention is extrapolated from broader GH pulsatility literature.

Doses outside this range appear in the literature but are less common. Some investigator protocols have used as little as 50 mcg in sensitivity studies; doses above 500 mcg per administration have been reported without proportional GH response and are not generally described as productive.

Stacking with CJC-1295

The most widely discussed ipamorelin combination in the research literature pairs it with CJC-1295, a GHRH analogue, on the rationale that the two act on different receptors and different limbs of the GH axis. GHRH analogues upregulate somatotroph GH synthesis and sensitize the cell to secretagogue stimulation; GHRPs trigger release of the expanded GH pool. The combination produces a larger GH pulse than either compound alone — a synergy documented in multiple clinical pharmacology papers on GHRH/GHRP co-administration, beginning with work by Bowers and colleagues in the 1990s.

Two forms of CJC-1295 appear in the literature, and the distinction matters when pairing with ipamorelin. CJC-1295 without DAC (sometimes called Mod GRF 1-29) has a half-life of approximately 30 minutes — short enough to preserve pulsatility. When co-administered with ipamorelin, both compounds clear on a similar timescale, and the resulting GH pulse remains discrete. This is the combination most commonly paired with the pulsatile dosing schedules described above.

CJC-1295 with DAC (Drug Affinity Complex) is a conjugated form that binds serum albumin and extends half-life to approximately one week. Continuous GHRH receptor stimulation over days raises baseline GH tone rather than producing discrete pulses. Co-administering ipamorelin with CJC-1295 with DAC produces a different pharmacological profile — closer to GH "bleed" with superimposed ipamorelin pulses — and is generally not the approach taken when the research goal is to preserve native pulsatility. Researchers typically select one CJC-1295 variant based on whether pulse preservation or sustained elevation is the experimental objective.

A common co-administration dose reported is 100 mcg ipamorelin with 100 mcg CJC-1295 no-DAC, two to three times daily. Both peptides are stable in the same reconstituted solution and are often drawn together for a single subcutaneous injection in research settings.

Reconstitution, storage, and handling

Ipamorelin is supplied as a lyophilized white powder, typically in 2 mg or 5 mg vials. Reconstitution follows standard peptide handling: bacteriostatic water (0.9% benzyl alcohol) is the preferred diluent for multi-use vials, while sterile water for injection may be used for single-use preparations. The diluent is added slowly down the side of the vial rather than directly onto the powder, and the vial is gently swirled — not shaken — until the powder is fully dissolved.

Dose volume is a matter of convenience. A 5 mg vial reconstituted with 2.5 mL of bacteriostatic water yields a 2 mg/mL concentration, at which 100 mcg corresponds to 0.05 mL (5 units on a standard U-100 insulin syringe). A 1 mL reconstitution of the same vial yields 5 mg/mL, useful when minimizing injection volume matters.

Storage recommendations in the literature and manufacturer documentation converge on:

• Lyophilized, unopened: stable at room temperature for weeks and at -20 °C for extended storage. Freezing of the unreconstituted powder is generally preferred for long-term storage.
• Reconstituted: refrigerated at 2–8 °C, with bacteriostatic water as the diluent, stability is commonly cited as up to 30 days. Some sources extend this to 60 days with strict cold-chain; others recommend shorter windows. Avoid repeated temperature cycling.
• Light exposure: ipamorelin, like most peptides, is photosensitive. Vials should be stored in opaque packaging or a dark refrigerator compartment.

Freezing a reconstituted solution is generally not recommended, as freeze-thaw cycles can disrupt peptide tertiary structure and reduce bioactivity.

Open questions

Several aspects of ipamorelin pharmacology remain underexplored in the published literature. Long-term receptor desensitization dynamics with chronic pulsatile dosing are not well characterized in humans — most clinical data cover weeks rather than months. Sex differences in GH response to ipamorelin, present in the broader GH literature, have not been systematically examined for this compound. The degree to which the "clean" profile observed at research doses holds at supraphysiological doses is similarly unresolved, as most published work has stayed within the 100–300 mcg band.

The interaction between ipamorelin-induced GH pulses and sleep architecture is another open area. While pre-bed dosing is convention, the question of whether the peptide modestly alters slow-wave sleep duration or quality — as some ghrelin-receptor ligands appear to — has not been directly addressed in controlled trials.

For researchers approaching the compound, the literature on GHRH/GHRP combinations (including pairings with CJC-1295 in both DAC and no-DAC forms) and the broader GH pulsatility framework developed by Bowers, Veldhuis, and others provides the most useful orientation beyond the compound-specific pharmacology summarized here.